Mark Higgins
Overview
Explore the profile of Mark Higgins including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
1400
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ilo K, Hallikeri P, Naathan H, Van Duren B, Higgins M, McNamara I, et al.
Arthroplast Today
. 2025 Feb;
30:101504.
PMID: 39959366
Background: This systematic review aims to evaluate the effectiveness and safety of custom femoral stems in primary total hip arthroplasty (THA) for patients with secondary osteoarthritis with abnormal hip anatomy....
2.
Quinn J, van Duren B, Berber R, Higgins M, Matar H, Manktelow A, et al.
Arthroplast Today
. 2025 Feb;
31:101593.
PMID: 39911248
Background: Debridement, antibiotics and implant retention (DAIR) procedure is well-established as a management option for acute periprosthetic joint infection (PJI). We investigated the infection eradication rates of DAIR procedures at...
3.
McKinnon C, Thorat T, Craft A, Higgins M
BMJ Open Respir Res
. 2024 Jul;
11(1.
PMID: 39074961
Background: Ivacaftor approval was extended to people with cystic fibrosis (CF) with ≥1 of 28 additional ivacaftor-responsive mutations in the USA in 2017 based on preclinical in vitro data. This...
4.
McNally P, Singh A, McColley S, Davies J, Higgins M, Liu M, et al.
J Cyst Fibros
. 2024 Apr;
23(3):429-435.
PMID: 38580563
Background: Ivacaftor (IVA) has been shown to be safe and efficacious in children aged ≥4 months with cystic fibrosis (CF) and CFTR gating variants. We evaluated safety, pharmacokinetics (PK), and...
5.
Canavan B, Higgins M, Murdoch D, Raffel C, Lau K, Scalia G, et al.
CASE (Phila)
. 2024 Mar;
8(3Part B):253-257.
PMID: 38524886
No abstract available.
6.
Kim C, Higgins M, Liu L, Volkova N, Zolin A, Naehrlich L
J Cyst Fibros
. 2024 Feb;
23(3):436-442.
PMID: 38402082
Background: Lumacaftor/ivacaftor (LUM/IVA) has been shown to be safe and efficacious in people with cystic fibrosis (CF) ≥1 year of age. To assess the impact of early LUM/IVA initiation on...
7.
Higgins M, Farietta T, Campbell D, Liu M, Ostrenga J, Elbert A, et al.
BMJ Open Respir Res
. 2023 May;
10(1).
PMID: 37230763
Background: Ivacaftor approval was extended to people with cystic fibrosis (CF) and an variant in 2014 in the USA. This observational, real-world, postapproval study evaluated long-term outcomes among people with...
8.
Flume P, Harris R, Paz-Diaz H, Ahluwalia N, Higgins M, Campbell D, et al.
J Cyst Fibros
. 2022 Dec;
22(3):464-470.
PMID: 36581484
Background: Study 661-110 (EXTEND) is a phase 3, open-label, three-part rollover study designed to assess the long-term safety and efficacy of tezacaftor/ivacaftor (TEZ/IVA) in participants aged ≥12 years homozygous for...
9.
Rayment J, Asfour F, Rosenfeld M, Higgins M, Liu L, Mascia M, et al.
Am J Respir Crit Care Med
. 2022 Jun;
206(10):1239-1247.
PMID: 35771568
Previous phase 3 trials showed that treatment with lumacaftor/ivacaftor was safe and efficacious in people aged ⩾2 years with cystic fibrosis (CF) homozygous for the mutation in (CF transmembrane conductance...
10.
McKone E, DiMango E, Sutharsan S, Barto T, Campbell D, Ahluwalia N, et al.
J Cyst Fibros
. 2020 Dec;
20(2):234-242.
PMID: 33339768
Background: Tezacaftor (TEZ)/ivacaftor (IVA) is an approved CFTR modulator shown to be efficacious and generally safe and well tolerated in people ≥12 years of age with cystic fibrosis (CF) homozygous...